We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital Pathology Solution Now Customized for Breast Cancer Diagnostics

By LabMedica International staff writers
Posted on 09 Sep 2013
A tissue-staining analysis tool has been made accessible within a digital pathology system and has been customized for breast cancer biomarkers.

Dako Denmark A/S (Glostrup, Denmark), an Agilent Technologies company, and Omnyx, LLC (Pittsbugh, PA, USA), a joint venture of General Electric Healthcare and the University of Pittsburgh Medical Center, are now providing a newly developed clinical image analysis system for digital pathology in Europe. More...
Dako has been using its expertise in staining and image analysis to develop algorithms that are incorporated into the Omnyx integrated digital pathology platform as part of Omnyx’s aim of providing pathologists with a comprehensive workflow. Now, also Dako’s “HercepTest” image analysis tool for tissue-stained slides is accessible in the Omnyx system and specifically customized for Dako’s breast cancer prognostic markers.

HercepTest is a semiquantitative immunohistochemical assay for specific determination of HER2 (c-erbB-2 onco-protein) overexpression. It is used for breast cancer tissues routinely processed for histological evaluation; also for formalin-fixed, paraffin-embedded (FFPE) cancer tissue from patients with metastatic gastric or gastroesophageal junction adenocarcinoma. HercepTest is indicated as an aid in the assessment of breast and gastric cancer patients for whom trastuzumab (Herceptin) treatment is being considered, and for breast cancer patients for whom pertuzumab (PERJETA) or ado-trastuzumab emtansine (KADCYLA) treatment is being considered.

By providing quantitative, reproducible results and more objective interpretation for HercepTest, the combined system improves accuracy and efficiency and enables a more confident diagnosis. “Omnyx envisions a future where image analysis and workflow empower pathologists to make confident clinical decisions ultimately leading to better patient care,” said Jim LaFrance, CEO of Omnyx. “Our partnership with Dako allows us to offer image analysis to clinicians who use Dako tests.”

Digital pathology holds much potential for standardizing test interpretation and enabling greater accuracy in tissue-based diagnostics. “With this offering, Dako and Omnyx support pathologists in making confident, efficient diagnoses based on both subjective and quantitative measures,” said Jakob Mohr Christensen, vice president of Global Marketing at Dako; “Additionally, the algorithms link digital scanners to Dako reagents and staining instruments, [providing] a complete and integrated solution.”

Related Links:

Omnyx, LLC
Dako



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.